-
1.发明授权公开(公告)号：US07923534B1
公开(公告)日：2011-04-12
申请号：US08819669
申请日：1997-03-17
申请人： Thierry Boon , Pierre Van Der Bruggen , Benoit Van Den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
发明人： Thierry Boon , Pierre Van Der Bruggen , Benoit Van Den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
IPC分类号： C07K14/435
CPC分类号： C07K14/4748 , A61K38/00 , A61K39/00 , C07K16/30 , Y10S530/806 , Y10S530/828
摘要： The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
摘要翻译： 本发明涉及编码由细胞毒性T细胞识别的肿瘤细胞表达的抗原的分离的DNA序列，导致表达肿瘤的裂解。 还描述了由DNA序列转染的细胞，以及由其编码的DNA和抗原的性质产生的各种治疗和诊断用途。
-
2.发明授权Tumor rejection antigen precursors, tumor rejection antigens and uses thereof 失效肿瘤排斥抗原前体，肿瘤排斥抗原及其用途
公开(公告)号：US5925729A
公开(公告)日：1999-07-20
申请号：US142368
申请日：1994-05-02
申请人： Thierry Boon , Pierre Van Der Bruggen , Benoit Van Den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
发明人： Thierry Boon , Pierre Van Der Bruggen , Benoit Van Den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
IPC分类号： A61K31/70 , A61K9/127 , A61K35/12 , A61K35/14 , A61K35/18 , A61K38/00 , A61K39/00 , A61K39/395 , A61K48/00 , A61P35/00 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/52 , C07K14/525 , C07K14/54 , C07K14/55 , C07K14/705 , C07K16/00 , C07K16/30 , C07K16/42 , C07K17/00 , C12N1/00 , C12N1/20 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/00 , C12N15/02 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/00 , C12Q1/68 , C12R1/19 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/577 , G01N33/68 , A61K38/08
CPC分类号： C07K14/4748 , C07K16/30 , A61K38/00 , A61K39/00 , Y10S530/806 , Y10S530/828
摘要： The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
摘要翻译： 本发明涉及编码由细胞毒性T细胞识别的肿瘤细胞表达的抗原的分离的DNA序列，导致表达肿瘤的裂解。 还描述了由DNA序列转染的细胞，以及由其编码的DNA和抗原的性质产生的各种治疗和诊断用途。
-
3.发明授权Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 失效编码肿瘤排斥抗原前体MAGE-1的核苷酸序列
公开(公告)号：US5342774A
公开(公告)日：1994-08-30
申请号：US807043
申请日：1991-12-12
申请人： Thierry Boon , Pierre van der Bruggen , Benoit Van den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
发明人： Thierry Boon , Pierre van der Bruggen , Benoit Van den Eynde , Aline Van Pel , Etienne De Plaen , Christophe Lurquin , Patrick Chomez , Catia Traversari
IPC分类号： A61K31/70 , A61K9/127 , A61K35/12 , A61K35/14 , A61K35/18 , A61K38/00 , A61K39/00 , A61K39/395 , A61K48/00 , A61P35/00 , C07K7/06 , C07K14/00 , C07K14/47 , C07K14/52 , C07K14/525 , C07K14/54 , C07K14/55 , C07K14/705 , C07K16/00 , C07K16/30 , C07K16/42 , C07K17/00 , C12N1/00 , C12N1/20 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/00 , C12N15/02 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/00 , C12Q1/68 , C12R1/19 , G01N33/50 , G01N33/53 , G01N33/574 , G01N33/577 , G01N33/68 , C07H15/12 , C07K3/00 , C12N1/16 , C12N1/18 , C12N5/00 , C12P19/34
CPC分类号： C07K16/30 , C07K14/4748 , A61K38/00 , A61K39/00
摘要： The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
摘要翻译： 本发明涉及编码由细胞毒性T细胞识别的肿瘤细胞表达的抗原的分离的DNA序列，导致表达肿瘤的裂解。 还描述了由DNA序列转染的细胞，以及由其编码的DNA和抗原的性质产生的各种治疗和诊断用途。
-
4.发明授权Isolated nonapeptides which bind to HLA molecules and provoke lysis by cytolytic T cells 失效分离的非肽结合HLA分子并引起细胞溶解T细胞裂解
公开(公告)号：US6034214A
公开(公告)日：2000-03-07
申请号：US354679
申请日：1994-12-13
申请人： Thierry Boon , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari
发明人： Thierry Boon , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari
CPC分类号： C07K16/30 , C07K14/4748 , A61K38/00 , A61K39/00
摘要： The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
摘要翻译： 本发明涉及由HLA分子接收特定的非肽。 所述非肽源自MAGE基因家族的表达产物。 所得复合物通过溶细胞T细胞鉴定。 这种识别可用于诊断或治疗。
-
公开(公告)号：US5405940A
公开(公告)日：1995-04-11
申请号：US938334
申请日：1992-08-31
申请人： Thierry Boon , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari
发明人： Thierry Boon , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari
CPC分类号： C07K16/30 , C07K14/4748 , A61K38/00 , A61K39/00
摘要： The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
摘要翻译： 本发明涉及由HLA分子接收特定的非肽。 所述非肽源自MAGE基因家族的表达产物。 所得复合物通过溶细胞T细胞鉴定。 这种识别可用于诊断或治疗。
-
公开(公告)号：US06488932B1
公开(公告)日：2002-12-03
申请号：US08571263
申请日：1995-12-12
申请人： Thierry Boon , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari
发明人： Thierry Boon , Pierre van der Bruggen , Etienne De Plaen , Christophe Lurquin , Catia Traversari
IPC分类号： C07K500
CPC分类号： C07K16/30 , A61K38/00 , A61K39/00 , C07K14/4748
摘要： The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
摘要翻译： 本发明涉及由HLA分子接收特定的非肽。 所述非肽源自MAGE基因家族的表达产物。 所得复合物通过溶细胞T细胞鉴定。 这种识别可用于诊断或治疗。
-
公开(公告)号：US07547439B1
公开(公告)日：2009-06-16
申请号：US09856812
申请日：1999-11-26
IPC分类号： A61K39/00
CPC分类号： C07K14/4748 , A61K38/00
摘要： Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
摘要翻译： 包含SEQ ID NO：1或2的不间断氨基酸序列的多肽具有与主要组织相容性复合物分子型HLA-A2复合的能力，优选HLA-A2.1的能力。
-
公开(公告)号：US07041502B2
公开(公告)日：2006-05-09
申请号：US10164078
申请日：2002-06-05
申请人： Janine Bilsborough , Erwin Schultz , Christophe Panichelli , Thierry Boon , Pierre Van der Bruggen
发明人： Janine Bilsborough , Erwin Schultz , Christophe Panichelli , Thierry Boon , Pierre Van der Bruggen
CPC分类号： G01N33/5008 , A61K39/00 , A61K39/0011 , A61K2039/515 , A61K2039/5158 , G01N33/5011 , G01N33/5047 , G01N33/505 , G01N33/5091 , G01N33/68
摘要： A peptide, previously identified as a binding partner of HLA-B44, has now been found to bind to HLA-B18 forming a T cell epitope. The therapeutic and diagnostic ramifications of this are the subject of this invention, as are various products obtained in the course of the development of the invention.
-
公开(公告)号：US10035851B2
公开(公告)日：2018-07-31
申请号：US15341077
申请日：2016-11-02
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/33 , C07K2317/565 , C07K2317/76 , G01N33/57488 , G01N2333/495 , G01N2800/52
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
-
公开(公告)号：US20170137507A1
公开(公告)日：2017-05-18
申请号：US15341077
申请日：2016-11-02
IPC分类号： C07K16/22
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/33 , C07K2317/565 , C07K2317/76 , G01N33/57488 , G01N2333/495 , G01N2800/52
摘要： Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-β1) are provided, particularly recognizing human and mouse TGF-β1 and not recognizing or binding TGF-β2 or TGF-β3. Particular antibodies are provided which specifically recognize and neutralize TGF-β1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-β1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-β1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.029 秒)
